Sure, it's possible Dr. Missling could match the cost of the other approved drugs or even try to ask for more because of the savings associated with not having to go for infusions and MRIs (although they're already working on an at-home injectable form of one of the antibody drugs).
I just don't see that happening. The cost to produce Blarcamesine is significantly less than other drugs as it's a small-molecule compound, and Dr. Missling comes from a European pedigree where profit is important but not the most important. If charging less means more insurers quickly agree to cover the cost and/or those who are paying out of pocket can still afford it, I think that's the path forward he's going to choose (and rightly so).
News 
Market Data 
Discover 
AI
